查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861440

生物工程蛋白療法市場按藥物類別、治療適應症、給藥途徑、最終用戶和技術平台分類－全球預測（2025-2032 年）

Bioengineered Protein Drugs Market by Drug Class, Therapeutic Indication, Route of Administration, End User, Technology Platform - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物工程蛋白質藥物市場將成長至 7,721.9 億美元，複合年成長率為 8.06%。

關鍵市場統計數據
基準年 2024 4151.3億美元
預計年份：2025年 4483.8億美元
預測年份 2032 7721.9億美元
複合年成長率 (%) 8.06%

一個簡潔的生物工程蛋白療法策略框架，將科學進步、不斷變化的法規和商業性需求與行業領導者的需求相結合。

生物工程蛋白療法領域處於分子創新、先進製造技術和不斷變化的臨床需求的關鍵交匯點。過去十年，表達系統、下游純化和分析表徵技術的進步，拓展了可在臨床和商業規模上可靠開發和生產的蛋白質種類。同時，全球監管機構日益關注產品可比性、免疫抗原性風險控制以及品質源於設計（QbD）框架，迫使申辦方將監管策略納入早期研發決策。

隨著相關人員應對日益複雜的價值鏈，策略重點正從單一產品上市轉向基於平台的方法，以降低技術風險並加速臨床試驗進程。投資者和企業研發團隊在評估資產時，不僅關注其治療潛力，還關注其可生產性、平台適應性和穩定的供應關係。因此，兼具卓越科學研究實力、靈活生產能力和清晰監管路徑的企業，更有能力將早期研發成果轉化為永續的臨床計畫。

本報告首先整合這些相互交織的力量，然後著重分析決策者必須掌控的營運、監管和商業槓桿。透過闡明科學進步如何與策略選擇相聯繫，本報告為深入探討市場變化、關稅影響、市場細分細微差別、區域動態、競爭行為以及為行業領導者提供的實用建議奠定了基礎。

分子設計、生物製程、監管指導和供應鏈韌性等方面的整合進展如何重塑各產業的策略重點

分子工程、表現技術和臨床應用領域的融合發展正在改變生物工程蛋白療法的模式。精準蛋白設計使得建構更複雜的蛋白質模式成為可能，例如多結構域融合蛋白和高度修飾的糖蛋白，從而提高了特異性並最佳化了藥物動力學特徵。同時，生物製程創新，例如強化灌流培養、一次性使用技術和連續下游加工，正在縮短研發週期並提高批次間一致性，從而能夠在滿足臨床需求的同時實現小規模生產。

監管機構正透過提供兼顧創新與病人安全的精細指導來應對這些技術變革，強調穩健的特性分析和全面的生命週期管理。監管的成熟推動了對正交分析方法、In Silico免疫抗原性評估以及早期研發階段基於生理資訊的藥物動力學模型的投資。在商業方面，支付方的嚴格審查和基於價值的合約正在重塑上市策略，要求企業提供真實世界證據以及超越傳統終點的差異化臨床獲益。

此外，供應鏈韌性已成為一項策略重點。為了降低地緣政治和產能風險，製藥業正轉向多元化製造地佈局，並增加合約研發生產機構（CDMO）的使用。因此，如今的競爭格局更青睞那些在藥物發現、平台工程、可擴展生產和核准後證據生成等方面具備綜合能力的企業，而那些能夠兼顧科學雄心和卓越營運的企業將成為新的贏家。

近期關稅措施對蛋白質治療項目的供應鏈、生產在地化和資本配置的營運和策略影響。

美國對生物製藥耗材和設備徵收關稅，為蛋白質療法研發和生產企業帶來了新的考量。關稅凸顯了籌資策略的重要性，迫使企業重新評估供應商合約、最佳化備件庫存並實現關鍵生產零件的本地化生產。在此背景下，許多企業開始權衡全球採購的靈活性和成本效益與近岸外包或國內採購的營運穩定性之間的利弊。

因此，資本配置決策正在轉變。企業優先考慮那些能夠降低跨境關稅波動風險的投資，例如加強本國或鄰近地區的生產能力、提高供應商冗餘度以及儲備關鍵試劑和耗材。這些調整也會影響與合約研發產量機構 (CDMO) 合作的經濟效益，因為受關稅影響的物流可能會改變成本結構並延長技術轉移前置作業時間。

從創新角度來看，關稅環境正在推動上游工程最佳化，以減少對易受關稅影響的投入品的依賴。例如，研發團隊正在探索替代表達系統、模組化製程設計以及節省試劑的分析方法，以保持專案進度。總體而言，關稅並未改變蛋白質治療藥物研發的科學基礎，但它們正在重塑營運風險狀況以及有關供應鏈設計、資本投資和合作夥伴選擇的策略決策。

透過按模態、治療領域、給藥途徑、終端用戶環境和表達平台進行綜合細分分析，指南開發和商業化策略。

詳細的細分分析表明，不同的給藥方式、適應症、給藥途徑、終端用戶環境和技術平台，各自對藥物的研發和商業化提出了不同的策略要求。考慮到藥物類別內部的差異，酵素製劑（包括Glucosidase和Asparaginase亞型）通常需要嚴格的安全監測和專門的輸注通訊協定。融合蛋白（分為Fc融合蛋白和受體融合蛋白）通常優先考慮延長半衰期和受體特異性靶向，以實現便捷給藥和擴大治療窗口。單株抗體種類繁多（嵌合體、全人源型、人源化型和鼠源型），其免疫抗原性考量和研發路徑各不相同。同時，聚乙二醇化蛋白（聚乙二醇化干擾素和其他聚乙二醇化治療藥物）需要仔細考慮與聚合物相關的安全性和清除問題。重組蛋白涵蓋廣泛的分子，包括促紅血球生成素的α和BETA異構體、生長因子如G-CSF、GM-CSF和PDGF、各種胰島素製劑（從中效到長效到速效）以及α、BETA和γ類干擾素，每一種都對製劑和穩定性提出了獨特的挑戰。

當治療領域的優先事項反映出不同治療方式的差異時，針對糖尿病和生長遲緩的內分泌項目強調長期給藥、患者依從性和居家給藥。血液學項目，例如貧血和出血性疾病，則著重於慢性疾病的急性治療模式和避免輸血。免疫學項目，例如發炎性腸道疾病、乾癬和類風濕性關節炎，需要長期治療的持續療效和安全性。同時，針對細菌和病毒感染疾病的感染疾病計畫往往優先考慮快速反應和聯合治療。在腫瘤學領域，骨髓惡性腫瘤和固態腫瘤之間的差異決定了其臨床開發路徑，涉及不同的生物標記、聯合治療和監管策略。

給藥途徑（肌肉注射、靜脈注射、皮下注射）的選擇會影響下游流程，例如製劑設計、醫療設備整合和病患用藥。針對最終用戶環境（例如診所、居家醫療或醫院環境）的設計，會影響包裝、低溫運輸物流以及安全給藥的教育要求。最後，技術平台的選擇，例如使用 CHO 或 NS0 細胞的哺乳動物細胞表達、使用大腸桿菌或酵母的微生物表達，或在動物或植物來源中的基因改造宿主表達，決定了上游工程工藝的複雜性、糖基化模式和監管證據要求。整合這些細分維度，使申辦方能夠客製化開發策略，並將特定治療方法的科學需求與生產、分銷和支付方參與等實際考量相結合。

區域監管差異、製造能力和市場進入趨勢對美洲、歐洲、中東和非洲以及亞太地區戰略執行的影響

區域趨勢對監管策略、供應鏈設計和商業性定位有顯著影響，因此需要針對每個主要全球區域制定量身定做的策略。在美洲，複雜的監管體系和先進的支付系統要求重點關注差異化的臨床效益、真實世界結果的收集以及可靠的生產實踐。該地區的市場進入策略通常依賴證明產品價值符合既定的醫療標準，因此，儘早與支付方和衛生技術評估機構接洽至關重要，以確保證據的產生符合報銷預期。

歐洲、中東和非洲地區（EMEA）面臨著更多元化的監管和商業環境，這不僅帶來了挑戰，也帶來了機會。歐洲監管機構對藥品品質和監管有嚴格的要求，而各國的報銷機制差異顯著，因此需要彈性價格設定和存取策略。在中東和非洲部分地區，生物製藥生產和低溫運輸物流的產能限制凸顯了戰略夥伴關係和區域技術轉移的重要性，以確保永續的供應和核准後支援。

亞太地區兼具前瞻性的監管機構和快速現代化的市場，促使當地生物製造、勞動力發展和公私合營進行大量投資。在該地區營運的公司必須應對多樣化的監管要求，加快本地證據的積累，並考慮能夠平衡本地生產與全球供應韌性的技術轉移模式。在所有地區，那些能夠積極調整監管計劃、製造地和市場進入策略以適應當地情況的公司，將更有利於克服准入壁壘，並在產品上市後取得持續成功。

為什麼平台擴充性、從開發到製造的整合能力以及能夠產生實證的夥伴關係是產業競爭優勢的核心？

生物工程蛋白領域的競爭格局正從以產品為中心的競爭演變為以能力為中心的競爭，其中最關鍵的差異化因素包括平台可擴展性、從研發到生產的一體化產品線以及產生令人信服的真實世界證據的能力。老牌製藥公司持續投資於平台技術和內部生產能力，以確保供應的連續性並獲取下游利潤，而規模較小的生物技術公司則專注於創新和特定臨床價值，並積極探索合作和收購機會。合約研發生產機構（CDMO）正扮演著日益重要的策略角色，它們提供模組化生產能力、法規支持，並加速產業對新型製程技術的應用。

夥伴關係模式日趨複雜，通常結合風險共擔、里程碑付款和分階段技術轉移等要素，以應對臨床和商業化階段的不確定性。投資強大的分析和品質平台的公司能夠縮短可比性驗證時間，降低後期法規核准意外情況發生的可能性，從而獲得競爭優勢。此外，能夠展示生命週期管理策略（例如配方最佳化和皮下及居家給藥設備的共同開發）的公司，其產品對支付方和醫療服務提供方的吸引力也會增強。

在人才和能力方面，能夠整合分子生物學、生物製程工程、法規科學和衛生經濟學的多學科團隊是產業優先考慮的因素。那些在這些領域培養內部專業知識或建立深厚外部夥伴關係的機構，將更有能力高效地執行複雜項目，並更靈活地應對不斷變化的臨床和報銷需求。

切實可行的優先事項，整合科學設計、供應鏈韌性、分析和市場進入規劃，以加速產品成功上市。

產業領導者應採取切實可行的優先事項，將科學潛力轉化為永續的商業性成果。首先，應協調藥物發現和製程開發，在分子設計早期階段就考慮可生產性、分析可追溯性和監管要求，以減少後續返工並加快決策速度。其次，應透過結合國內和區域生產以及與合約研發生產機構 (CDMO) 的策略合作，實現供應鏈多元化，以降低關稅和地緣政治風險，同時保持產能擴張的靈活性。

第三，儘早投資正交分析和免疫抗原性風險評估工具，以降低臨床開發風險並建立強大的可比性方案。第四，將市場進入規劃融入臨床開發，確保終點指標、病患報告結局和真實世界證據收集能夠支持從首次人體試驗到核准後階段的健保報銷談判。第五，推行基於平台的商業化策略，以便在多個專案中快速重新部署製程知識和生產資產，從而提高資本效率並縮短後續候選藥物的上市時間。

最後，領導者應組成涵蓋研發、監管事務、生產製造和市場進入等多個領域的跨學科團隊，並加強與學術機構和技術合作夥伴的外部合作，以確保獲得新的能力。這些共同努力將建立一個具有韌性的營運結構，既能支持創新，又能應對將複雜蛋白質療法交付給患者的實際限制。

嚴謹的混合方法研究，結合專家訪談、技術文獻、監管審查和跨職能三角驗證，以支持可操作的策略洞察。

本分析整合了多層次的一手和二手研究，以得出平衡且基於證據的結論。一手研究包括對藥物發現、製程開發、生產製造、法規事務和商業化等部門的行業高管進行結構化訪談，並輔以針對生物製程工程師和市場進入專家的諮詢。二手研究涵蓋了同行評審文獻、監管指導文件、上市公司披露資訊以及重點介紹表達系統、工藝強化和分析技術最新進展的技術白皮書。

我們的分析方法結合了相關人員訪談的定性主題編碼和已記錄趨勢的跨職能三角驗證，以識別持續存在的策略模式和新出現的營運風險。在適當情況下，我們整合了技術轉移、平台部署和供應鏈調整的案例，以闡明其實際意義。我們的調查方法強調資料來源的透明度，傾向於對方向性趨勢進行保守的解讀而非推測性的預測，並優先考慮可操作的見解而非毫無根據的推論。

品管包括同行評審員的交叉檢驗、領域專家對技術聲明的檢驗，以及對關稅風險和製造地等營運因素的敏感度分析。最終形成結構化的綜合分析報告，為策略決策提供依據，並識別出需要持續監測和重點研究的不確定性領域。

策略整合凸顯了科學創新與強大營運體系的整合對於實現永續的患者可及性和商業性成功至關重要。

總之，生物工程蛋白療法的未來發展軌跡將由兩大關鍵要素決定：一是持續推動科學創新，二是建構能夠將分子潛能轉化為可靠病患用藥途徑的運作體系。分子設計和製造技術的進步拓展了治療的可能性，同時也對分析方法、監管規劃和供應鏈策略提出了新的要求。那些致力於彌合從藥物發現到最終交付鴻溝的機構，例如透過設計可製造性、投資多元化的生產路徑以及提供能夠吸引支付方和醫療服務提供方的證據，將更有能力應對競爭壓力和複雜的監管環境。

關稅和不斷變化的貿易環境凸顯了主動進行供應鏈風險管理的必要性，而區域監管差異則強調了客製化打入市場策略的重要性。最終，該領域的成功取決於平台開發、品管和准入規劃等方面的嚴格執行，以及能夠加速能力獲取的靈活夥伴關係。透過優先考慮這些相互關聯的要素，企業不僅可以推動有前景的治療方法進入臨床試驗階段，還能建立一條永續的路徑，最終造福患者。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 雙特異性抗體工程技術的進步增強了腫瘤標靶化
  • 整合人工智慧驅動的蛋白質設計以最佳化治療效果和特異性
  • 利用mRNA編碼蛋白療法加速標靶細胞內蛋白表達
  • 常規流動無細胞蛋白合成平台規模化挑戰與創新
  • 生物相似藥產品組合的不斷擴大加劇了全球價格競爭。
  • 透過基於奈米顆粒的標靶遞送系統提高蛋白質療法的生物利用度
  • 監管協調工作旨在加快新型蛋白質藥物的核准途徑。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 生物工程蛋白藥物市場（依藥物類別分類）

  • 酵素
    • Glucosidase
    • Asparaginase
  • 融合蛋白
    • Fc融合蛋白
    • 受體融合蛋白
  • 單株抗體
    • 嵌合體
    • 完全人類
    • 人性化
    • 老鼠
  • 聚乙二醇化蛋白
    • 聚乙二醇化干擾素
    • 聚乙二醇化療法
  • 重組蛋白
    • 促紅血球生成素
      • 阿爾法
      • BETA
    • 生長因子
      • G-CSF
      • GM-CSF
      • PDGF
    • 胰島素
      • 中間型
      • 長效
      • 快速起效
    • 干擾素
      • 阿爾法
      • BETA
      • 伽瑪

9. 依治療適應症分類的生物工程蛋白藥物市場

  • 內分泌學
    • 糖尿病
    • 生長遲緩
  • 血液學
    • 貧血
    • 出血性疾病
  • 免疫學
    • 發炎性腸道疾病
    • 銀屑病
    • 類風濕性關節炎
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

10. 生物工程蛋白藥物市場（依給藥途徑分類）

  • 肌肉內注射
  • 靜脈注射
  • 皮下注射

第11章 生物工程蛋白藥物市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

12. 依技術平台分類的生物工程蛋白藥物市場

  • 哺乳動物細胞表達
    • CHO細胞
    • NS0細胞
  • 微生物表達
    • 大腸桿菌
    • 酵母菌
  • 基因改造宿主表達
    • 動物源性
    • 植物來源

第13章 生物工程蛋白質藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物工程蛋白藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生物工程蛋白藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
Product Code: MRR-69324464D0EE

The Bioengineered Protein Drugs Market is projected to grow by USD 772.19 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 415.13 billion
Estimated Year [2025] USD 448.38 billion
Forecast Year [2032] USD 772.19 billion
CAGR (%) 8.06%

A concise strategic framing of bioengineered protein therapeutics that aligns scientific advances, regulatory evolution, and commercial imperatives for leaders

The field of bioengineered protein therapeutics occupies a pivotal position at the intersection of molecular innovation, advanced manufacturing, and evolving clinical demand. Over the past decade, improvements in expression systems, downstream purification, and analytical characterization have expanded the range of protein modalities that can be reliably developed and produced at clinical and commercial scale. At the same time, regulators worldwide have intensified focus on product comparability, immunogenicity risk mitigation, and quality-by-design frameworks, driving sponsors to integrate regulatory strategy with early development decisions.

As stakeholders navigate increasingly complex value chains, strategic priorities have shifted from single-product launches toward platform-based approaches that reduce technical risk and shorten time to clinic. Investors and corporate development teams are evaluating assets not only for their therapeutic potential but also for manufacturability, platform adaptability, and the robustness of supply relationships. Consequently, organizations that combine scientific excellence with flexible manufacturing and a clear regulatory pathway are better positioned to convert early-stage promise into sustainable clinical programs.

This report opens with a synthesis of those converging forces and frames the subsequent analysis around the operational, regulatory, and commercial levers that decision-makers must manage. By clarifying how scientific advances map to strategic choices, the introduction sets the stage for a deeper examination of market shifts, tariff implications, segmentation nuances, regional dynamics, competitive behaviors, and actionable recommendations for leaders in the field.

How convergent advances in molecular design, bioprocessing, regulatory guidance, and supply chain resilience are reshaping strategic priorities across the sector

The landscape for bioengineered protein drugs is undergoing transformative shifts driven by convergent advances in molecular engineering, expression technologies, and clinical application. Precision engineering of proteins has enabled more complex modalities, including multi-domain fusion constructs and heavily modified glycoproteins, which offer enhanced specificity and tailored pharmacokinetic profiles. Concurrently, bioprocess innovations such as intensified perfusion culture, single-use technologies, and continuous downstream processing are reducing development timelines and improving batch-to-batch consistency, thereby enabling smaller-scale production that nevertheless meets clinical demand.

Regulatory authorities are responding to these technological changes with nuanced guidance that balances innovation with patient safety, emphasizing robust characterization and lifecycle control. This regulatory maturation has encouraged sponsors to invest in orthogonal analytics, in silico immunogenicity assessment, and physiologically informed pharmacokinetic modeling earlier in development. Commercially, payer scrutiny and value-based contracting are reshaping launch strategies, prompting companies to demonstrate real-world evidence and differentiated clinical benefit beyond traditional endpoints.

Moreover, supply chain resilience has become a strategic priority. The industry is moving toward diversified manufacturing footprints and expanded use of contract development and manufacturing organizations to mitigate geopolitical and capacity risks. As a result, the competitive landscape now rewards integrated capabilities that span discovery, platform engineering, scalable manufacturing, and post-approval evidence generation, creating new winners among organizations that can synchronize scientific ambition with operational excellence.

Operational and strategic consequences of recent tariff measures on supply chains, manufacturing localization, and capital allocation for protein therapeutic programs

The introduction of tariff measures affecting biologics-related inputs and equipment in the United States has introduced new considerations for developers and manufacturers of protein therapeutics. Tariffs increase the importance of input sourcing strategies, compelling organizations to reassess supplier contracts, spare parts inventories, and localization of critical manufacturing components. In this context, many companies have begun to evaluate the trade-offs between the flexibility and cost benefits of global sourcing and the operational stability afforded by nearshoring or domestic procurement.

Consequently, capital deployment decisions have shifted: firms are prioritizing investments that reduce exposure to cross-border tariff volatility, including onshore or nearshore manufacturing capacity, strengthened supplier redundancy, and inventory buffering for critical reagents and consumables. These adaptations also influence the economics of collaboration with contract development and manufacturing organizations, where tariff-impacted flows change comparative cost structures and can extend lead times for technology transfer.

From an innovation standpoint, the tariff environment has encouraged upstream optimization to reduce reliance on tariff-exposed inputs. For example, development teams are exploring alternative expression systems, modular process architectures, and reagent-sparing analytics to maintain program momentum. Overall, while tariffs do not alter the scientific rationale for advancing protein therapeutics, they do reshape operational risk profiles and the strategic calculus around supply chain design, capital investment, and partnership selection.

Integrated segmentation analysis connecting modalities, therapeutic areas, administration routes, end-user environments, and expression platforms to inform development and commercialization strategy

A nuanced segmentation analysis reveals how modality, indication, administration route, end-user environment, and technology platform each create distinct strategic imperatives for development and commercialization. Examining drug class distinctions shows that enzymes, including subtypes such as alglucosidase and asparaginase, typically demand focused safety monitoring and specialized infusion protocols, whereas fusion proteins split between Fc fusion proteins and receptor fusion proteins often prioritize extended half-life and receptor-specific targeting to enhance dosing convenience and therapeutic window. Monoclonal antibodies, spanning chimeric, fully human, humanized, and murine variants, vary in immunogenicity considerations and development pathways, while PEGylated proteins-both PEGylated interferon and other PEGylated therapies-require attention to polymer-related safety and clearance. Recombinant proteins encompass a wide set of molecules such as erythropoietin with alpha and beta isoforms, growth factors including G-CSF, GM-CSF, and PDGF, various insulin formulations from intermediate to long and rapid acting, and interferons across alpha, beta, and gamma classes, each bringing modality-specific formulation and stability challenges.

Translating modality-level nuance into therapeutic-area priorities, endocrinology programs for diabetes mellitus and growth disorders emphasize chronic administration, patient adherence, and home-based delivery, while hematology targets like anemia and bleeding disorders focus on acute-on-chronic treatment paradigms and transfusion-sparing outcomes. Immunology indications such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis demand durable efficacy and safety over extended treatment horizons, whereas infectious diseases programs for bacterial and viral infections often prioritize rapid onset and combination strategies. Oncology's split between hematological malignancies and solid tumors creates divergent clinical development pathways, with different biomarker, combination, and regulatory strategies.

Route of administration choices-intramuscular, intravenous, and subcutaneous-have downstream implications for formulation, device integration, and patient access. End-user considerations spanning clinic, home care, and hospital settings shape packaging, cold-chain logistics, and educational requirements for safe administration. Finally, technology platform selection between mammalian cell expression with CHO and NS0 lines, microbial expression leveraging E. coli and yeast, and transgenic host expression via animal-based or plant-based systems determines upstream process complexity, glycosylation patterns, and regulatory evidence expectations. Integrating these segmentation dimensions allows sponsors to tailor development strategies that align modality-specific scientific needs with practical considerations for manufacturing, distribution, and payer engagement.

How regional regulatory diversity, manufacturing capacity, and market access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shape strategic execution

Regional dynamics exert strong influence over regulatory strategy, supply chain design, and commercial positioning, and they require tailored approaches across the major global blocs. In the Americas, regulatory sophistication and advanced payer systems drive emphasis on differentiated clinical benefit, real-world outcomes collection, and high-integrity manufacturing practices. Market access strategies in this region often hinge on demonstrating value against established standards of care, necessitating early engagement with payers and health technology assessment bodies to align evidence generation with reimbursement expectations.

Across Europe, Middle East & Africa, the regulatory and commercial landscape is more heterogeneous, presenting both challenges and opportunities. European regulatory agencies maintain rigorous expectations for quality and pharmacovigilance, while reimbursement mechanisms vary substantially by country, driving the need for flexible pricing and access strategies. In parts of the Middle East and Africa, capacity constraints in biologics manufacturing and cold-chain logistics amplify the importance of strategic partnerships and regional technology transfer to ensure sustainable supply and post-approval support.

The Asia-Pacific region features a blend of advanced regulatory authorities and rapidly modernizing markets, with significant investments in local biomanufacturing, talent development, and public-private collaboration. Sponsors engaging in this region must navigate diverse regulatory requirements, accelerate local evidence generation, and consider technology-transfer models that support both regional production and global supply resilience. Across all regions, firms that proactively align regulatory planning, manufacturing footprints, and market access approaches to local conditions will navigate entry barriers more effectively and sustain post-launch success.

Why platform scalability, integrated development-manufacturing capabilities, and evidence-generation partnerships are becoming the core competitive differentiators in the industry

Competitive behavior in the bioengineered protein space is evolving from product-centric rivalry toward capability-centric competition, where the most decisive differentiators are platform scalability, integrated development-to-manufacturing pipelines, and the ability to generate compelling real-world evidence. Established pharmaceutical companies continue to invest in platform technologies and in-house production capacity to secure supply continuity and capture downstream margin, while smaller biotechnology firms focus on innovation and niche clinical value to attract collaboration or acquisition. Contract development and manufacturing organizations play an increasingly strategic role, offering modular capacity, regulatory support, and faster industry adoption of novel process technologies.

Partnership models are becoming more sophisticated, often combining risk-share elements, milestone-based payments, and staged technology transfer to manage uncertainty across clinical and commercial phases. Companies that invest in robust analytical and quality platforms gain a competitive edge by shortening comparability timelines and reducing the probability of late-stage regulatory surprises. Moreover, firms that can demonstrate lifecycle management strategies, including formulation optimization and device co-development for subcutaneous and home-administration use cases, increase the attractiveness of their assets to payers and providers.

From a talent and capability perspective, the industry is prioritizing cross-disciplinary teams that bridge molecular biology, bioprocess engineering, regulatory science, and health economics. Organizations that cultivate internal expertise in these areas or secure deep external partnerships position themselves to execute complex programs more efficiently and to respond nimbly to evolving clinical and reimbursement demands.

Practical, executable priorities for leaders to integrate scientific design, supply chain resilience, analytics, and market access planning to accelerate successful product launches

Industry leaders should adopt a set of actionable priorities to convert scientific promise into sustained commercial performance. First, align discovery and process development to ensure that early molecular design choices account for manufacturability, analytical tractability, and regulatory expectations, thereby reducing downstream rework and accelerating decision gates. Second, diversify supply chain arrangements through a combination of onshore, nearshore, and strategic CDMO partnerships to mitigate tariff and geopolitical risk while maintaining flexibility in capacity scaling.

Third, make early investments in orthogonal analytics and immunogenicity risk assessment tools to de-risk clinical development and support robust comparability packages. Fourth, integrate market access planning into clinical development so that endpoints, patient-reported outcomes, and real-world evidence collection support reimbursement discussions from first-in-human stages through post-approval. Fifth, pursue platform-based commercialization strategies that allow for the rapid redeployment of process knowledge and manufacturing assets across multiple programs, thereby improving capital efficiency and time-to-market for follow-on candidates.

Finally, leaders should build multidisciplinary teams that bridge R&D, regulatory affairs, manufacturing, and market access, and they should foster external collaboration with academic centers and technology partners to access emerging capabilities. These combined actions create a resilient operational posture that supports innovation while managing the practical constraints of bringing complex protein therapeutics to patients.

A rigorous mixed-methods research approach combining expert interviews, technical literature, regulatory review, and cross-functional triangulation to support practical strategic insights

This analysis synthesizes primary and secondary research layers to ensure balanced, evidence-based conclusions. Primary inputs included structured interviews with industry executives across discovery, process development, manufacturing, regulatory affairs, and commercial functions, supplemented by targeted expert consultations with bioprocess engineers and market access specialists. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, public company disclosures, and technical white papers that illuminate recent advances in expression systems, process intensification, and analytics.

Analytical approaches combined qualitative thematic coding of stakeholder interviews with cross-functional triangulation of documented trends, enabling identification of persistent strategic patterns and emergent operational risks. Where relevant, case examples of technology transfer, platform deployment, and supply chain adaptation were synthesized to illustrate practical implications. The methodology emphasized transparency in data provenance and a conservative interpretation of directional trends rather than speculative projections, prioritizing actionable insight over unsupported extrapolation.

Quality controls included reviewer cross-checks, validation of technical claims with subject-matter experts, and sensitivity analysis around operational drivers such as tariff exposure and manufacturing footprint. The result is a structured synthesis designed to inform strategic decision-making while acknowledging areas of uncertainty that warrant ongoing monitoring and targeted research.

A strategic synthesis emphasizing the necessity of integrating scientific innovation with robust operational systems to deliver sustainable patient access and commercial success

In closing, the trajectory of bioengineered protein therapeutics is defined by a dual imperative: sustain scientific innovation while building operational systems that translate molecular promise into reliable patient access. Technological advances in molecular design and manufacturing are expanding therapeutic possibilities, yet they also raise new requirements for analytics, regulatory planning, and supply chain strategy. Organizations that intentionally bridge the gap between discovery and delivery-by designing for manufacturability, investing in diversified production pathways, and generating evidence that speaks to payers and providers-will be better equipped to navigate competitive pressures and regulatory complexity.

The evolving tariff and trade environment reinforces the need for proactive supply chain risk management, while regional regulatory heterogeneity underscores the value of tailored market entry strategies. Ultimately, success in this space will depend on disciplined execution across platform development, quality control, and access planning, coupled with agile partnerships that accelerate capability acquisition. By prioritizing these interconnected elements, companies can not only advance promising therapies through clinical pipelines but also establish durable pathways to patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in bispecific antibody engineering for enhanced tumor targeting
  • 5.2. Integration of AI-driven protein design to optimize therapeutic potency and specificity
  • 5.3. mRNA-encoded protein therapies accelerating targeted intracellular protein expression
  • 5.4. Scale-up challenges and innovations in continuous flow cell-free protein synthesis platforms
  • 5.5. Expansion of biosimilar protein drug portfolios intensifying global pricing competition
  • 5.6. Nanoparticle-based targeted delivery systems improving bioavailability of protein therapeutics
  • 5.7. Regulatory harmonization efforts enabling faster approval pathways for novel protein drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bioengineered Protein Drugs Market, by Drug Class

  • 8.1. Enzymes
    • 8.1.1. Alglucosidase
    • 8.1.2. Asparaginase
  • 8.2. Fusion Proteins
    • 8.2.1. Fc Fusion Proteins
    • 8.2.2. Receptor Fusion Proteins
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Chimeric
    • 8.3.2. Fully Human
    • 8.3.3. Humanized
    • 8.3.4. Murine
  • 8.4. PEGylated Proteins
    • 8.4.1. PEGylated Interferon
    • 8.4.2. PEGylated Therapies
  • 8.5. Recombinant Proteins
    • 8.5.1. Erythropoietin
      • 8.5.1.1. Alpha
      • 8.5.1.2. Beta
    • 8.5.2. Growth Factors
      • 8.5.2.1. G-CSF
      • 8.5.2.2. GM-CSF
      • 8.5.2.3. PDGF
    • 8.5.3. Insulin
      • 8.5.3.1. Intermediate Acting
      • 8.5.3.2. Long Acting
      • 8.5.3.3. Rapid Acting
    • 8.5.4. Interferons
      • 8.5.4.1. Alpha
      • 8.5.4.2. Beta
      • 8.5.4.3. Gamma

9. Bioengineered Protein Drugs Market, by Therapeutic Indication

  • 9.1. Endocrinology
    • 9.1.1. Diabetes Mellitus
    • 9.1.2. Growth Disorders
  • 9.2. Hematology
    • 9.2.1. Anemia
    • 9.2.2. Bleeding Disorders
  • 9.3. Immunology
    • 9.3.1. Inflammatory Bowel Disease
    • 9.3.2. Psoriasis
    • 9.3.3. Rheumatoid Arthritis
  • 9.4. Infectious Diseases
    • 9.4.1. Bacterial Infections
    • 9.4.2. Viral Infections
  • 9.5. Oncology
    • 9.5.1. Hematological Malignancies
    • 9.5.2. Solid Tumors

10. Bioengineered Protein Drugs Market, by Route of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Bioengineered Protein Drugs Market, by End User

  • 11.1. Clinic
  • 11.2. Home Care
  • 11.3. Hospital

12. Bioengineered Protein Drugs Market, by Technology Platform

  • 12.1. Mammalian Cell Expression
    • 12.1.1. CHO Cells
    • 12.1.2. NS0 Cells
  • 12.2. Microbial Expression
    • 12.2.1. E. coli
    • 12.2.2. Yeast
  • 12.3. Transgenic Host Expression
    • 12.3.1. Animal Based
    • 12.3.2. Plant Based

13. Bioengineered Protein Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bioengineered Protein Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bioengineered Protein Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Amgen Inc.
    • 16.3.5. Novartis AG
    • 16.3.6. Merck & Co., Inc.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Sanofi S.A.
    • 16.3.9. Bristol-Myers Squibb Company
    • 16.3.10. Eli Lilly and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY C